ArriVent BioPharma (AVBP) Retained Earnings (2023 - 2026)

ArriVent BioPharma (AVBP) has 4 years of Retained Earnings data on file, last reported at $772.2 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 355.11% year-over-year to $772.2 million; the trailing twelve-month figure through Mar 2026 stood at $772.2 million (up 355.11% YoY), and the FY2025 full-year result was $14000.0, down 100.0% from the prior year.
• Retained Earnings advanced to $772.2 million in Q1 2026, from $14000.0 in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $772.2 million in Q1 2026 to a low of -$369.1 million in Q3 2025.
• A 4-year average of $39.0 million and a median of -$87.6 million in 2024 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings jumped 10566.27% in 2024 and slumped 174.54% in 2025, its largest moves.
• Tracing AVBP's Retained Earnings over 4 years: stood at $4.7 million in 2023, then jumped by 10566.27% to $496.2 million in 2024, then slumped by 100.0% to $14000.0 in 2025, then surged by 5515657.14% to $772.2 million in 2026.
• Business Quant data shows AVBP's Retained Earnings at $772.2 million in Q1 2026, $14000.0 in Q4 2025, and -$369.1 million in Q3 2025.